Lapatinib inhibits stem/progenitor proliferation in preclinical in vitro models of ductal carcinoma in situ (DCIS).
MetadataShow full item record
AbstractBreast-conserving surgery for ductal carcinoma in situ (DCIS) is often combined with irradiation, reducing recurrence rates to 20% within 10 years; however, there is no change in overall survival. Evidence in the invasive breast indicates that breast cancer stem cells (CSCs) are radiotherapy-resistant and are capable of re-initiating a tumor recurrence; hence, targeting CSCs in high risk DCIS patient may improve survival. HER2 is overexpressed in 20% of DCIS and is known to be highly active in breast CSCs; we therefore investigated the effect of Lapatinib on DCIS CSC activity using 2 in vitro culture systems. Two DCIS cell lines DCIS.com (HER2 normal) and SUM225 (HER2 overexpressed) as well as DCIS cells from patient samples (n = 18) were cultured as mammospheres to assess CSC activity and in differentiated 3D-matrigel culture to determine effects within the non-CSCs. Mammosphere formation was reduced regardless of HER2 status, although this was more marked within the HER2-positive samples. When grown as differentiated DCIS acini in 3D-matrigel culture, Lapatinib only reduced acini size in the HER2-positive samples via decreased proliferation. Further investigation revealed lapatinib did not reduce self-renewal activity in the CSC population, but their proliferation was decreased regardless of HER2 status. In conclusion we show Lapatinib can reduce DCIS CSC activity, suggesting that the use of Lapatinib in high-risk DCIS patients has the potential to reduce recurrence and the progression of DCIS to invasive disease.
CitationLapatinib inhibits stem/progenitor proliferation in preclinical in vitro models of ductal carcinoma in situ (DCIS). 2013, 13 (3): Cell Cycle
- Combined inhibition of ErbB1/2 and Notch receptors effectively targets breast ductal carcinoma in situ (DCIS) stem/progenitor cell activity regardless of ErbB2 status.
- Authors: Farnie G, Willan PM, Clarke RB, Bundred NJ
- Issue date: 2013
- Molecular effects of lapatinib in patients with HER2 positive ductal carcinoma in situ.
- Authors: Estévez LG, Suarez-Gauthier A, García E, Miró C, Calvo I, Fernández-Abad M, Herrero M, Marcos M, Márquez C, Lopez Ríos F, Perea S, Hidalgo M
- Issue date: 2014 Sep 4
- Everolimus Inhibits the Progression of Ductal Carcinoma <i>In Situ</i> to Invasive Breast Cancer Via Downregulation of MMP9 Expression.
- Authors: Chen G, Ding XF, Pressley K, Bouamar H, Wang B, Zheng G, Broome LE, Nazarullah A, Brenner AJ, Kaklamani V, Jatoi I, Sun LZ
- Issue date: 2020 Mar 15
- Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast.
- Authors: Barnes NL, Khavari S, Boland GP, Cramer A, Knox WF, Bundred NJ
- Issue date: 2005 Mar 15
- Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ.
- Authors: Curigliano G, Disalvatore D, Esposito A, Pruneri G, Lazzeroni M, Guerrieri-Gonzaga A, Luini A, Orecchia R, Goldhirsch A, Rotmensz N, Bonanni B, Viale G
- Issue date: 2015 Apr